✦ LIBER ✦

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP

✍ Scribed by Ming-Shen Dai; Tsu-Yi Chao; Woei-Yau Kao; Rong-Yaun Shyu; Tan-Mei Liu

Publisher: Springer
Year: 2004
Tongue: English
Weight: 187 KB
Volume: 83
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-004-0899-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Retrospective analysis of hepatitis B vi

Retrospective analysis of hepatitis B virus reactivation after rituximab combination chemotherapy in patients with B-cell lymphoma

✍ Yun Fan; Chong Luo; Lvhong Luo; Zhiyu Huang; Haifeng Yu 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 234 KB

Reactivation of hepatitis B virus after

Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma

✍ Kosei Matsue; Shun-Ichi Kimura; Yoko Takanashi; Kan-Ichi Iwama; Hideaki Fujiwara 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Preemptive use of interferon or lamivudi

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy

✍ ShiangJiin Leaw; ChiaJui Yen; WenTsung Huang; TsaiYun Chen; WuChou Su; ChaoJung 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 139 KB

Possible efficacy of lamivudine treatmen

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma

✍ Y. Tsutsumi; J. Tanaka; T. Kawamura; T. Miura; H. Kanamori; S. Obara; M. Asaka; 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 106 KB

P168 Hepatitis B virus reactivation in a

P168 Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with immuno-chemotherapy (including fludarabine and rituximab)

✍ Zs. Ujj; L. Rejtö; I. Tornai; A. Kiss; B. Telek; Gy. Reményi; P. Ilonczai; M. Ud 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 45 KB

was longer on retreatment (11 months) than at first treatment (6 months). It is of special interest, that this patient was 83 years old when treated first with radioimmunotherapy and tolerated it on both occasions without side effects or severe cytopenias. In another patient with severe accompanying